Martin Yang, Oppenheimer senior analyst, joins 'Squawk on the Street' to discuss what Apple Intelligence is lacking that's ...
Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after the ...
According to estimates by IDC and Canalys, overall iPhone market share fell 1% year over year in Q4 to 23% despite the ...
Investors were hoping that Apple Intelligence would drive a wave of iPhone upgrades. How's that playing out? This will be the first full quarter of results from Apple since the company's iPhone 16 ...
Apple ( AAPL, Financials) was downgraded to Perform from Outperform by Oppenheimer ahead of its first-quarter fiscal 2025 ...